LifeStance Health Group, Inc. (LFST)
NASDAQ: LFST · Real-Time Price · USD
6.49
+0.12 (1.81%)
Apr 24, 2025, 4:00 PM EDT - Market closed
LifeStance Health Group Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for LifeStance Health Group stock have an average target of 8.30, with a low estimate of 7.00 and a high estimate of 10. The average target predicts an increase of 27.99% from the current stock price of 6.49.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for LifeStance Health Group stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Keybanc | Keybanc | Buy Initiates $9 | Buy | Initiates | $9 | +38.78% | Apr 8, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +23.36% | Apr 3, 2025 |
| Goldman Sachs | Goldman Sachs | Hold → Strong Buy Upgrades $10 | Hold → Strong Buy | Upgrades | $10 | +54.20% | Dec 16, 2024 |
| Barclays | Barclays | Sell Maintains $6 → $7 | Sell | Maintains | $6 → $7 | +7.94% | Nov 11, 2024 |
| UBS | UBS | Hold Maintains $9 → $7.5 | Hold | Maintains | $9 → $7.5 | +15.65% | Aug 15, 2024 |
Financial Forecast
Revenue This Year
1.45B
from 1.25B
Increased by 15.59%
Revenue Next Year
1.65B
from 1.45B
Increased by 13.97%
EPS This Year
-0.10
from -0.15
EPS Next Year
-0.03
from -0.10
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 1.5B | 1.7B | 2.0B | |
| Avg | 1.4B | 1.6B | 1.9B | |
| Low | 1.4B | 1.6B | 1.8B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 19.4% | 19.0% | 20.5% | |
| Avg | 15.6% | 14.0% | 15.7% | |
| Low | 10.8% | 8.2% | 9.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.04 | 0.05 | 0.19 |
| Avg | -0.10 | -0.03 | 0.08 |
| Low | -0.15 | -0.12 | -0.10 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.